Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

This was the stock's fourth consecutive day of losses.

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...

Regeneron (REGN) and Sanofi (SNY) announce successful Phase 3 outcome for Dupixent in bullous pemphigoid, but not in chronic ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...